<DOC>
	<DOCNO>NCT02384954</DOCNO>
	<brief_summary>This Phase I/II , open-label , multi-center , competitive enrollment dose escalation study ALT-803 patient relapse/refractory indolent B cell non-Hodgkin lymphoma conjunction rituximab .</brief_summary>
	<brief_title>QUILT-3.002 : ALT-803 Patients With Relapse/Refractory iNHL Conjunction With Rituximab</brief_title>
	<detailed_description>The purpose study evaluate safety tolerability , identify Maximum Tolerated Dose ( MTD ) Minimum Efficacious Dose ( MED ) designate dose level Phase 2 . Also characterize immunogenicity , pharmacokinetic profile , biomarker serum level ALT-803 treat patient . The effect ALT-803 peripheral absolute lymphocyte count white blood cell count , number , phenotype repertoire peripheral blood T ( total subset ) NK cell evaluate . In addition , subset patient evaluate change lymph node immune composition . Anti-tumor response survival data also collect trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis iNHL ( Follicular lymphoma grade 1 , 2 , 3a ; marginal zone lymphoma ; small lymphocytic lymphoma lymphoplasmacytic lymphoma ) treatment least 1 prior rituximabcontaining regimen . AntiCD20 mAbrefractory disease define progressive disease rituximab ( another treatment antiCD20 monoclonal antibody ) progression within 6 month rituximabcontaining ( another treatment antiCD20 antibodycontaining ) therapy . AntiCD20 mAbsensitive disease define response prior rituximabcontaining ( another treatment antiCD20 monoclonal antibody ) regimen , relapse 6 month last administration rituximabcontaining ( another treatment antiCD20 antibodycontaining ) therapy . Measurable disease : At least one lymph node group ≥ 1.5 cm long transverse dimension . Patients cutaneous disease may enrol clearly measurable skin lesion . Relapsed Refractory iNHL progress follow 1 prior systemic rituximabcontaining ( another treatment antiCD20 antibodycontaining ) regimens lymphoma PRIOR/CONCURRENT THERAPY : No antilymphoma treatment within 28 day start study treatment . Must recover side effect prior treatment . PATIENT CHARACTERISTICS : Performance Status • ECOG 0 , 1 , 2 Renal Function • Glomerular Filtration Rate ( GFR ) &gt; 40mL/min Serum creatinine ≤ 1.5 X ULN Bone Marrow Reserve Platelets ≥30,000/uL Hemoglobin ≥ 8g/dL Absolute Lymphocytes ≥800/uL ANC/AGC ≥750/uL Hepatic Function Total bilirubin ≤ 2.0 X ULN ( unless Gilbert 's Syndrome disease infiltration liver present ) AST , ALT ≤ 3.0 X ULN , ≤ 5.0 X ULN ( liver lymphoma present ) No positive Hep C serology active Hep B infection Cardiovascular No congestive heart failure &lt; 6 month No unstable angina pectoris &lt; 6 month No myocardial infarction &lt; 6 month No history ventricular arrhythmia severe cardiac dysfunction No history uncontrollable supraventricular arrhythmia No NYHA Class &gt; II CHF No mark baseline prolongation QT/QTc interval Pulmonary • Normal clinical assessment pulmonary function Other Negative serum pregnancy test female childbearing potential Women pregnant nursing Subjects , female male , reproductive potential must agree use effective contraceptive measure duration study No know autoimmune disease correct hypothyroidism No know prior organ allograft allogeneic transplantation Not HIV positive No active CNS involvement lymphoma No psychiatric illness/social situation would limit compliance No illness opinion investigator would exclude subject participate study Must provide inform consent HIPPA authorization agree comply protocolspecified procedure followup evaluation No active systemic infection require parenteral antibiotic therapy No disease require systemic immunosuppressive therapy ( inhaled topical steroid allow ) . Adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent permit absence active autoimmune disease . No known histologic transformation iNHL DLBCL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>indolent B Cell</keyword>
	<keyword>non-Hodgkin Lymphoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Interleukin-15</keyword>
	<keyword>Absolute Lymphocyte Count</keyword>
	<keyword>White Blood Cell</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Lymphoplasmacytic Lymphoma</keyword>
	<keyword>anti-CD20</keyword>
</DOC>